A. Baseline characteristics | |||
---|---|---|---|
Characteristics (n = 168) | ≤ 14 days | > 14 days | p |
n | 59 | 106 | |
Male (%) | 38 (64.4) | 58 (54.7) | 0.334 |
Age (median [IQR]) | 65.00 [57.00, 69.50] | 67 [59, 73] | 0.109 |
BMI (median [IQR]) | 25.52 [23.20, 29.49] | 25.10 [22.50, 28.33] | 0.474 |
Performance status (%) | 0.747 | ||
0 | 23 (65.7) | 47 (71.2) | |
1 | 10 (28.6) | 17 (25.8) | |
2 | 2 (5.7) | 2 (3.0) | |
Jaundice (%) | 47 (79.7) | 67 (63.2) | 0.044* |
Diagnosed during hospital stay (%) | 30 (50.8) | 45 (42.5) | 0.382 |
Tumor location (%) | 0.3 | ||
Head | 51 (87.9) | 82 (78.1) | |
Body | 3 (5.2) | 10 (9.5) | |
Tail | 4 (6.9) | 13 (12.4) | |
Lymphadenopathy at imaging (%) | 9 (21.4) | 18 (20.2) | 1 |
Endoscopic biliary drainage (%) | 10 (20.8) | 46 (65.7) | < 0.001* |
Radiological biliary drainage (%) | 1 (2.1) | 5 (7.1) | 0.422 |
Total bilirubin (µmol/L) (median [IQR]) | 173.00 [74.25, 304.50] | 21.00 [8.00, 84.75] | < 0.001* |
Conjugated bilirubin (µmol/L) (median [IQR]) | 140.50 [60.50, 236.25] | 22.00 [4.00, 76.50] | < 0.001* |
Neutrophil-to-lymphocyte ratio (median [IQR]) | 2.67 [2.06, 4.09] | 2.68 [1.92, 3.52] | 0.223 |
B. Surgery procedure, histopathological, and follow up characteristics stratified on a 14 days-time to surgery n total population; IQR interquartile range; NA not available; *statistical significance | |||
---|---|---|---|
Characteristics (n = 168) | ≤ 14 days | > 14 days | p |
n | 59 | 106 | |
Type of resection (%) | 0.497 | ||
Duodenopancreatectomy | 50 (84.7) | 79 (74.5) | |
Splenopancreatectomy | 7 (11.9) | 20 (18.9) | |
Left pancreatectomy | 1 (1.7) | 3 (2.8) | |
Total pancreatectomy | 1 (1.7) | 4 (3.8) | |
Vein resection (%) | 16 (27.1) | 52 (49.1) | 0.01* |
Organ resection (%) | 4 (6.8) | 6 (5.7) | 1 |
T (%) | 0.375 | ||
1 | 0 (0.0) | 3 (2.9) | |
2 | 6 (10.2) | 18 (17.3) | |
3 | 49 (83.1) | 77 (74.0) | |
4 | 4 (6.8) | 5 (4.8) | |
x | 0 (0.0) | 1 (1.0) | |
N (%) | 0.488 | ||
0 | 11 (18.6) | 26 (24.8) | |
1 | 48 (81.4) | 78 (74.3) | |
x | 0 (0.0) | 1 (1.0) | |
M (%) | 0.111 | ||
0 | 53 (89.8) | 101 (96.2) | |
1 | 6 (10.2) | 3 (2.9) | |
x | 0 (0.0) | 1 (1.0) | |
Invaded/sampled lymph nodes (median [IQR]) | 0.06 [0.00, 0.15] | 0.10 [0.00, 0.20] | 0.403 |
Resection status = 1 (%) | 23 (39.0) | 38 (36.2) | 0.852 |
Microscopic vascular thrombosis (%) | 38 (84.4) | 64 (79.0) | 0.612 |
Perineural invasion (%) | 50 (92.6) | 86 (93.5) | 1 |
Hemorrhage (%) | 10 (25.6) | 11 (16.2) | 0.351 |
Fistula (%) | 12 (31.6) | 28 (41.2) | 0.442 |
Severe complications (%) | 15 (25.4) | 26 (24.5) | 1 |
Length of stay (days) (median [IQR]) | 21.00 [15.00, 28.00] | 19.00 [13.25, 25.00] | 0.416 |
Adjuvant chemotherapy (%) | 52 (91.2) | 87 (82.9) | 0.222 |
Number of chemotherapy cycles (median [IQR]) | 6.00 [5.50, 6.00] | 6.00 [5.33, 6.00] | 0.710 |
Adjuvant radiotherapy (%) | 4 (7.0) | 9 (8.6) | 1.000 |
Local disease recurrence (%) | 0 (0) | 6 (5.7) | |
Distant disease recurrence (%) | 48 (81.3) | 72 (74.5) | 0.761 |
Lymph node recurrence (%) | 12 (35.3) | 24 (43.6) | 0.578 |
Liver recurrence (%) | 21 (61.8) | 24 (43.6) | 0.149 |
Peritoneal recurrence (%) | 5 (14.7) | 10 (18.2) | 0.893 |
Other (%) | 10 (29.4) | 14 (25.5) | 0.871 |
Death (%) | 41 (69.5) | 70 (66.0) | 0.779 |
Time from surgery to adjuvant chemotherapy (days) (median [IQR]) | 55.00 [43.50, 74.50] | 54.00 [42.75, 63.00] | 0.543 |